Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice
Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice
复制标题
DOI：
10.2217/mmt-2019-0016
复制
发表时间：
2019-12-01
影响因子：
3.6
通讯作者：
Swetter, Susan M.
中科院分区：
文献类型：
--
作者：
Grossman, Douglas;Kim, Caroline C.;Swetter, Susan M.
在临床试验之外，目前的指南不建议对皮肤黑色素瘤（CM）进行预后基因表达谱（GEP）检测。然而，它们的使用变得越来越普遍，一些从业者正在使用GEP测试来指导患者管理。因此，迫切需要通过获得高质量的证据来弥合测试使用和临床指南建议之间的差距，以指导我们在CM患者中使用GEP测试的最佳实践。在这里，我们专注于机会和不确定性与预后GEP测试在CM，审查如何将GEP测试纳入葡萄膜黑色素瘤和乳腺癌的临床护理指南，并讨论临床试验的作用，以确定最佳使用在CM患者。
Prognostic gene expression profiling (GEP) tests for cutaneous melanoma (CM) are not recommended in current guidelines outside of a clinical trial. However, their use is becoming more prevalent and some practitioners are using GEP tests to guide patient management. Thus, there is an urgent need to bridge this gap between test usage and clinical guideline recommendations by obtaining high-quality evidence to guide us toward best practice use of GEP testing in CM patients. We focus here on the opportunities and uncertainties associated with prognostic GEP testing in CM, review how GEP testing was incorporated into clinical care guidelines for uveal melanoma and breast cancer and discuss the role of clinical trials to determine best use in patients with CM.